Dramatic lifestyle changes can fight early-stage Alzheimer's, study says. Here's how
As her memory faded from Alzheimer's disease in her late 50s, Tammy Maida began to lose track of her life. Car keys, eyeglasses and her purse disappeared multiple times a day. Key characters in novels she was reading were forgotten. Groceries were left in the garage. Keeping the books for the family's businesses became impossible.
'I honestly thought I was losing my mind, and the fear of losing my mind was frightening,' Maida told CNN Chief Medical Correspondent Dr. Sanjay Gupta in the 2024 CNN documentary 'The Last Alzheimer's Patient.'
After 20 weeks in a randomized clinical trial designed to drastically change her diet, exercise, stress levels and social interactions, Maida's cognition improved. She was able to read and recall novels and correctly balance spreadsheets again. A blood test even found levels of amyloid, a hallmark of Alzheimer's disease, were retreating in her brain, according to the study published in June 2024.
'I'm coming back. It was really good — like I was prior to the disease being diagnosed,' Maida, now 68, told a researcher on the study. 'An older but better version of me.'
Maida's cognition showed additional improvement, however, after she completed a total of 40 weeks of intensive lifestyle changes, said principal investigator Dr. Dean Ornish, a clinical professor of medicine at the University of California, San Francisco, and creator of the Ornish diet and lifestyle medicine program.
Ornish gave a study update on Tuesday at the 2025 Alzheimer's Association International Conference in Toronto.
While not everyone in the 26-person interventional group benefited, 46% showed improvement in three of four standardized tests, he said, including one that measures changes in memory, judgment and problem-solving as well as the ability to function at home, practice hobbies and practice personal hygiene.
'An additional 37.5% of people showed no decline in cognition during those 40 weeks,' Ornish said. 'Thus, over 83% of patients improved or maintained their cognition during the five-month program.'
The new findings mirrored those of other studies on lifestyle interventions, he said, including the recent US POINTER study, the largest clinical trial in the United States to test moderate lifestyle interventions over two years in people who are at risk but do not yet have Alzheimer's disease.
'Our study complements these findings by showing, for the first time, that more intensive lifestyle changes may often stop or even begin to reverse the decline in cognition in many of those who already have Alzheimer's disease, and these improvements often continue over a longer period of time,' Ornish told CNN.
And unlike available medications for Alzheimer's, he added, lifestyle changes have no side effects, such as bleeding and swelling in the brain that may occur with the newest class of drugs.
EmblemHealth, a New York-based insurance company, announced Tuesday that it will be the first health insurer to cover the Ornish lifestyle medicine program for patients who have early-stage Alzheimer's disease.
The lifestyle intervention Ornish created — which he calls 'eat well, move more, stress less and love more' — has been tested before. In 1990, Ornish showed for the first time in a randomized clinical trial that coronary artery disease could often be reversed with nothing more than diet, exercise, stress reduction and social support.
The US Centers for Medicare and Medicaid Services, or CMS, declared in 2010 that Ornish's program for reversing heart disease was an 'intensive cardiac rehabilitation' and that it would be eligible for reimbursement under Medicare.
Additional research has shown the same four-part program can lower blood sugars and heart disease risk in patients with diabetes, reduce prostate cancer cell growth, improve depression and even lengthen telomeres, the protective caps of chromosomes that are worn away by aging.
During the Ornish intervention, one group of people consumed a strict vegan diet, did daily aerobic exercise, practiced stress reduction and engaged in online support groups. The rest of the participants were in a control group and were asked to not make any changes in their daily habits.
Therapists led hour-long group sessions three times a week in which participants were encouraged to share their feelings and ask for support. Meditation, deep breathing, yoga and other ways to reduce stress took up another hour every day. The program also encouraged participants to prioritize good-quality sleep.
Supplements were provided to everyone in the intervention group, including a daily multivitamin, omega-3 fatty acids with curcumin, coenzyme Q10, vitamin C and B12, magnesium, a probiotic, and Lion's mane mushroom.
In addition to online strength training led by a physical trainer, people in the intervention attended hour-long video classes on vegan nutrition hosted by a dietitian. Then, to ensure a vegan diet was followed, all meals and snacks for both participants and their partners were delivered to their homes.
Complex carbs found in whole grains, vegetables, fruits, tofu, nuts and seeds made up most of the diet. Sugar, alcohol and refined carbs found in processed and ultraprocessed foods were taboo. While calories were unrestricted, protein and total fat made up only some 18% of the daily caloric intake — far less than the typical protein intake by the average American, Ornish said.
People in the intervention group who put the most effort into changing their lifestyle have the most improvement in their cognition, said Ornish, founder and president of the nonprofit Preventive Medicine Research Institute and coauthor of 'Undo It! How Simple Lifestyle Changes Can Reverse Most Chronic Diseases.'
'There was a statistically significant dose-response relationship between the degree of adherence to our lifestyle changes and the degree of improvement we saw on measures of cognition,' Ornish said.
The 25 people in the study's original 20-week control group — who did not receive the intervention — had shown further cognitive decline during the program. They were later allowed to join the intervention for 40 weeks and significantly improved their cognitive scores during that time, Ornish said.
It all makes sense, said co-senior study author Rudy Tanzi, an Alzheimer's researcher and professor of neurology at Harvard Medical School in Boston.
'If you picture a brain full of damage as a sink full of water, when you just turn off the tap, it takes a long time for that sink to slowly drain, right?' Tanzi told CNN in 2024. 'If you want the amyloid to go down in 20 weeks, as we found on one blood test, you're going to need a Roto-Rooter.'
In the 2024 study, a blood test called plasma Aβ42/40 showed a significant improvement in the original intervention group. Aβ42/40 measures the level of amyloid in the blood, a key symptom of Alzheimer's.
Tests that measure amyloid in different ways, however, did not show improvement, Dr. Suzanne Schindler, an associate professor of neurology at Washington University School of Medicine in St. Louis who specializes in blood biomarkers told CNN at the time.
There was no significant change in a test for amyloid called p-tau 181, considered to be a superior measure of Alzheimer's risk, said Schindler, who was not involved in the study. Nor was there any change in glial fibrillary acidic protein, or GFAP, another blood biomarker that seems to correlate reasonably well with Alzheimer's disease.
'If one of these markers improves, you typically see all of them improve, so the fact they did not makes me wonder whether this effect is real,' Schindler said. 'If they were to repeat the study with a much larger population for a longer period of time, perhaps more change could be seen.'
Over the complete 40-week program, however, a number of people in the intervention group did continue to improve their Aβ42/40 scores, according to the study update.
'Changes in amyloid — as measured as the plasma Aβ42/40 ratio — occur before changes in tau markers such as p-tau 218, so this is not surprising after only 40 weeks,' Ornish said.
For Ornish, who has watched members of his family die from Alzheimer's disease, the study's results are important for one key reason — hope.
'So often when people get a diagnosis of dementia or Alzheimer's, they are told by their doctors that there is no future, 'It's only going to get worse, get your affairs in order.' That's horrible news and is almost self-fulfilling,' Ornish said.
'Our new findings empower patients who have early-stage Alzheimer's disease with the knowledge that if they make and maintain these intensive lifestyle changes, there is a reasonably good chance that they may slow the progression of the disease and often even improve it,' he said.
'Our study needs to be replicated with larger, more diverse groups of patients to make it more generalizable,' Ornish said. 'But the findings we reported today are giving many people new hope and new choices — and the only side effects are good ones.'
See Full Web Article
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Epoch Times
30 minutes ago
- Epoch Times
Scientists Accidentally Discover Laser-Free LASIK Alternative
A chemistry professor trying to heat cartilage with electricity made a mistake that could change eye surgery. Michael Hill at Occidental College accidentally used too little current in his experiment—and stumbled upon a discovery that might replace LASIK with a gentler treatment that reshapes corneas without ever cutting the eye. The discovery may offer hope for the millions of people living with poor vision who want an alternative to glasses and contact lenses but are wary of LASIK's risks. While laser eye surgery is generally successful, it involves cutting into the eye and can cause complications including dry eyes, vision problems, and in rare cases, severe side effects. Happy Accident Behind the Discovery The breakthrough happened entirely by chance when Hill and his collaborator, Dr. Brian Wong, a professor of otolaryngology-head and neck surgery at the University of California–Irvine, were frustrated with their attempts to reshape cartilage using lasers.
Yahoo
3 hours ago
- Yahoo
Cholesterol Isn't Just About Heart Health—It May Be the Missing Link In Alzheimer's, Says New Study
"Hearst Magazines and Yahoo may earn commission or revenue on some items through these links." A new study suggests that there's a link between how well you move cholesterol to the neurons in your brain and Alzheimer's disease. This factor is connected to the APOE4 genetic variant, which significantly increases your risk of developing the disease. Here's what to know and what this means for Alzheimer's research. Alzheimer's disease sparks a cascade of changes throughout the body that lead to a slew of debilitating symptoms. But there's one surprising biological change that researchers are just starting to uncover, thanks to a new study. The study, which was published in the Journal of Lipid Research, found that people with Alzheimer's disease experience a breakdown in the ability to shuttle cholesterol to the neurons in their brain, and that this symptom is linked to a certain genetic variant called APOE4, which carries a known risk for Alzheimer's. This biological discovery could potentially pave the way for a better understanding of the disease and even future disease prevention methods. Here's what you need to know about the science so far, with input from a neurologist. Meet the expert: Clifford Segil, DO, is a neurologist at Providence Saint John's Health Center in Santa Monica, CA. What did the researchers find? For the study, researchers analyzed the cerebrospinal fluid (the biological liquid that surrounds and cushions the brain and spinal cord) from 10 patients with Alzheimer's disease and compared it to the cerebrospinal fluid of 10 people who did not have the condition. They discovered that lipoproteins (round particles made of fat and protein) in the cerebrospinal fluid of Alzheimer's patients were less effective at delivering cholesterol to neurons, or nerve cells, which are responsible for transmitting information from the brain throughout the body. What is cholesterol? Cholesterol is an essential, waxy, fat-like molecule that your body needs for good health, according to the National Heart Lung and Blood Institute (NHLBI). Cholesterol is carried around your body by two types of lipoproteins: low-density lipoproteins (a.k.a. LDL or 'bad' cholesterol) and high-density lipoproteins (a.k.a. HDL or 'good' cholesterol). High levels of LDL cholesterol can cause a buildup of fatty deposits called plaque in your arteries, raising the risk of heart attack, stroke, and other health complications, per the NHLBI. But high levels of good HDL cholesterol may lower the risk for certain health issues. Why is it important for brain function? While it has a bad rap in the health world, cholesterol is actually really important for your proper brain function. Your brain is the most cholesterol-rich organ in your body. Specifically, cholesterol helps make up cell membranes, including those in nerve cells, and plays a crucial role in your neurons' ability to "talk" to each other and transmit information. When cholesterol levels are out of balance, it can impact that transmission of essential information between nerve cells, leading to cognitive issues that are seen with neurodegenerative diseases like Alzheimer's disease. Cholesterol is also a building block for steroid hormones, which support brain function. However, that doesn't mean more cholesterol is always good for your brain. High levels of LDL cholesterol are usually considered a modifiable risk factor for ischemic stroke, or 'clogged pipes' in the brain, explains Clifford Segil, DO, a neurologist at Providence Saint John's Health Center in Santa Monica, CA. 'There is less research and understanding on the possible benefits of cholesterol found in spinal fluid including HDL, which we classically identify as the 'good cholesterol,'' Dr. Segil says. 'We know high levels of certain types of cholesterol cause strokes and we are less clear in the year 2025 about the benefits of cholesterol in brain function.' How does this link back to Alzheimer's? This particular study noted that cholesterol found in lipoproteins were different in patients with Alzheimer's disease, but Dr. Segil says that there is a 'complicated' relationship between lipids and protein in the brain. 'Some researchers continue to assign memory loss symptoms in patients with Alzheimer's due to abnormal brain protein levels and this paper noted lipid brain levels may also be abnormal,' he says. Dr. Segil points out that neurologists commonly prescribe medications called statins to lower levels of cholesterol and the risk of stroke. Lowering levels of LDL cholesterol can decrease the risk of developing certain type of dementia, including vascular dementia, he says. But it's not clear if it may do more. 'Further research will determine if lowering your cholesterol will result in lower chances of getting Alzheimer's dementia,' he says. You Might Also Like Jennifer Garner Swears By This Retinol Eye Cream These New Kicks Will Help You Smash Your Cross-Training Goals Solve the daily Crossword
Yahoo
5 hours ago
- Yahoo
Anavex Life Pre-Treatment Prevented Cognitive Impairment In Animal Model of Alzheimer's Disease, New Publication Shows
Anavex Life Sciences Corp. (NASDAQ:AVXL) reported a peer-reviewed publication in the journal Neuroscience Letters on Wednesday. The study shows that a pre-treatment with blarcamesine prevented Amyloid beta-induced memory impairment and brain oxidative injury. "This preclinical study is exciting since it clearly demonstrates a preventative effect of blarcamesine in Alzheimer's pathology and potentially might be able to prevent onset of Alzheimer's disease in healthy individuals," said Tangui Maurice, PhD, Research Director at the University of Montpellier, France and author of the placebo-controlled mice developed significant amyloid toxicity in the brains after the toxic Aβ25-35 peptide injection, in animals pre-treated with blarcamesine, significant protection was observed, with less vulnerability to Aβ25-35-induced oxidative stress and less vulnerability to develop learning and memory deficits. The mechanistic confirmation that blarcamesine particularly restores impaired autophagy through SIGMAR1 activation by acting upstream of amyloid and tau pathologies at the molecular level was previously established in vitro and in vivo. Blarcamesine studies demonstrated the effect of enhanced autophagic flux in human cells and in C. elegans, as well as increased proteostasis capacity and ability to promote autophagosome biogenesis, autophagic cargo reception, and lysosome fusion. SIGMAR1 has emerged as a key therapeutic target in the treatment of neurodegenerative disorders. Its activation enhances autophagy, facilitating the degradation of amyloid-beta precursor protein (APP) and helping to normalize Aβ production. SIGMAR1 activation supports neurogenesis, mitigates oxidative stress by reducing reactive oxygen species (ROS), suppresses neuroinflammatory responses, and alleviates Aβ-induced toxicity. It also plays a critical role in maintaining endoplasmic reticulum (ER) integrity and modulating intracellular calcium signaling. Collectively, these effects contribute to restoring cellular homeostasis, rebalancing neural function, and promoting neuroplasticity. In April, Anavex Life Sciences announced that over three years of continuous treatment with blarcamesine (ANAVEX 2-73) demonstrated significant amelioration of clinical decline, showing continued clinical and meaningful benefit for early Alzheimer's disease patients. Price Action: AVXL stock is up 1.59% at $9.59 during the premarket session at the last check on Wednesday. Read Next:Photo via Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? This article Anavex Life Pre-Treatment Prevented Cognitive Impairment In Animal Model of Alzheimer's Disease, New Publication Shows originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data